07:00 , Apr 28, 2016 |  BC Innovations  |  Distillery Techniques

Techniques: Synthetic biology-based protocol to differentiate human induced pluripotent stem (iPS) cell-derived pancreatic progenitors into mature β-like cells

Drug platforms TECHNOLOGY: Cell therapy A synthetic lineage-control network could program human iPS cell-derived pancreatic progenitor cells into mature β-like cells used to treat diabetes. In human iPS cell-derived pancreatic progenitors, expression of a synthetic lineage-control network...
07:00 , Mar 24, 2016 |  BC Innovations  |  Translation in Brief

Stomaching insulin production

A Harvard University study suggests antral stomach cells share enough features with pancreatic β cells that they can be coached to play the part. The authors think direct reprogramming of this renewable, accessible stomach cell...
08:00 , Feb 25, 2016 |  BC Innovations  |  Distillery Techniques

Techniques: In vivo reprogramming of stomach cells into insulin-secreting pancreatic β-like cells

Drug platforms TECHNOLOGY: Cell therapy Insulin-secreting pancreatic β-like cells derived from renewable stomach cells could help treat diabetes. In mice, gastrointestinal and antral stomach enteroendocrine cells were engineered to express three human genes - neurogenin 3 (Ngn3;...
07:00 , May 15, 2014 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Direct in vivo reprogramming of pancreatic acinar cells into d-like and a-like pancreatic cells Direct in vivo reprogramming of...
08:00 , Feb 18, 2010 |  BC Innovations  |  Tools & Techniques

Bypassing the iPS logjam

Researchers atthe Stanford University School of Medicinehave found a way to efficiently convert mouse fibroblasts into functional neurons without first reverting the skin cells to a pluripotent state.1 The protocol could make it possible to...
07:00 , Sep 11, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Endocrine disease ...
07:00 , Sep 11, 2008 |  BC Innovations  |  Cover Story

Making a Hard Cell

A trio of papers suggests that transforming one differentiated cell type into another can be accomplished without the need for pluripotent, stem cell-like intermediates. Stem cell companies, however, don't think their technologies will be obviated...